Swedish Orphan Biovitrum Secures FDA Safety Nod for NASP, Focuses on CMC Resubmission
FDA’s CRL for SOBI’s NASP therapy highlights CMC and manufacturing fixes needed, but confirms safety and efficacy, boosting investor confidence and market outlook.
3 minutes to read